References
- John Hopkins University. Conditions and diseases → influenza [cited 2023 Mar 13]. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/influenza
- Macias AE, McElhaney JE, Chaves SS, et al. The disease burden of influenza beyond respiratory illness. Vaccine. 2021;39(Suppl 1):A6–A14.
- Shrestha S, Foxman B, Berus J, et al. The role of influenza in the epidemiology of pneumonia. Sci Rep. 2015;5:15314.
- Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(26):2540–2541.
- Boehme AK, Luna J, Kulick ER, et al. Influenza‐like illness as a trigger for ischemic stroke. Ann Clin Transl Neurol. 2018;5(4):456–463.
- World Health Organization. Fact sheet: influenza (seasonal); 2018 [cited 2020 Nov 6]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal)
- Finnish Institute for Health and Welfare (THL); 2020. Available from: https://thl.fi/en/web/infectious-diseases-and-vaccinations/surveillance-and-registers/infectious-diseases-in-finland-publications
- Pechirra P, Cristóvão P, Costa I, et al. Programa Nacional de Vigilância da Gripe: relatório da época 2018/2019. Lisboa: Instituto Nacional de Saúde Doutor Ricardo Jorge IP (INSA); 2019.
- Froes F, Carmo M, Lopes H, et al. Excess hospitalizations and mortality associated with seasonal influenza in Portugal, 2008–2018. BMC Infect Dis 2022;22: 726.
- Paget J, Iuliano AD, Taylor RJ, et al. Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project. Vaccine. 2022;40(9):1361–1369.
- World Health Organization. 2013. Available from: https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/vaccination/seasonal-vaccination-policies-and-coverage-in-the-european-region
- Carrat F, Vergu E, Ferguson NM, et al. Timelines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775–785.
- Roguski KM, Rolfes MA, Reich JS, et al. Variability in published rates of influenza-associated hospitalizations: a systematic review, 2007–2018. J Glob Health. 2020;10(2):020430.
- Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300.
- Centers for Disease Control and Prevention. Frequently asked questions about estimated flu burden: deaths; 2020 [cited 2021 Feb 2]. Available from: https://www.cdc.gov/flu/about/burden/faq.htm
- European Centre for Disease Prevention and Control. Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over. ECDC; 2020.
- Pepin S, Nicolas JF, Szymanski H, et al. QHD00011 study team. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized phase III trial. Hum Vaccin Immunother. 2021;17(12):5475–5486.
- Falsey A, Treanor J, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200(2):172–180.
- DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–645.
- Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018;17(5):435–443.
- DiazGranados CA, Robertson CA, Talbot HK, et al. Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine. 2015;33(38):4988–4993.
- Conseil Supérieur de la Santé. Avis DU Conseil Superieur DE LA Sante N° 9625; 2021.
- Finnish Institute for Health and Welfare (THL). Influenza vaccine. Available from: https://thl.fi/en/web/infectious-diseases-and-vaccinations/vaccines-a-to-z/influenza-vaccine
- Direçao Geral de Saúde. Normas e circulares normativas. Vacinação contra a gripe. Época 2021/2022; 2021. Available from: https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-0062021-de-25092021.aspx
- World Health Organization. Guidance on the economic evaluation of influenza vaccination; 2016.
- World Health Organization. WHO guide on standardization of economic evaluations of immunization programmes; 2019 [cited 2020 May 1]. Available from: https://www.who.int/immunization/documents/who_ivb_19.10/en/
- Redondo E, Drago G, López-Belmonte JL, et al. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine. Vaccine. 2021;39(36):5138–5145.
- Mattock R, Gibbons I, Moss J, et al. Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales. J Med Econ. 2021;24(1):1261–1271.
- Somes MP, Turner RM, Dwyer LJ, et al. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: a systematic review and meta-analysis. Vaccine. 2018;36(23):3199–3207.
- National Advisory Committee on Immunization. An Advisory Committee Statement (ACS). Literature review update on the efficacy and effectiveness of high-dose (Fluzone® high-dose) and MF59-adjuvanted (Fluad®) trivalent inactivated influenza vaccines in adults 65 years of age and older; 2018.
- Michaelis K, Scholz S, Buda S, et al. Beschluss und Wissenschaftliche Begründung der Ständigen Impfkommission (STIKO) für die Aktualisierung der Influenza-Impfempfehlung für Personen im Alter von ≥ 60 Jahren. Epid Bull. 2021;1:3–25.
- Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2022–23 influenza season. MMWR Recomm Rep. 2022;71(1):1–28.
- Chang LJ, Meng Y, Janosczyk H, et al. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: a phase 3 randomized clinical trial. Vaccine. 2019;37:5825–5834.
- Kapiainen S, et al. Terveydenhuollon yksikkökustannukset Suomessa. THL; 2014. Available from: https://urn.fi/URN:ISBN:978-952-302-079-5
- Szende A, Janssen B, Cabases J. (Eds) Self-reported population health: an international perspective based on EQ-5D. Dordrecht, Heidelberg, New York, London: Springer; 2014.
- Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10(7):621–635.
- Ferreira LN, Ferreira PL, Pereira LN, et al. The valuation of the EQ-5D in Portugal. Qual Life Res. 2014;23(2):413–423.
- Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003;7(35) doi: 10.3310/hta7350
- Baguelin M, Camacho A, Flasche S, et al. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study. BMC Med. 2015;13:236.
- Base de dados de medicamentos de uso humano; 2021. Available from: https://extranet.infarmed.pt/INFOMED-fo/index.xhtml
- Beutels P, Vandendijck Y, Willem L et al, Seasonal influenza vaccination: prioritizing children or other target groups? - Part II. Health Technology Assessment (HTA). Brussels. Belgian Health Care Knowledge Centre (KCE). 2013. KCE Reports 204. Aavilable from: https://kce.fgov.be/en/publications/all-reports/seasonal-influenza-vaccination-prioritizing-children-or-other-target-groups-part-ii
- Swartenbroekx N, Obyn C, Guillaume P, et al. Manual for cost-based pricing of hospital interventions. Health Technology Assessment (HTA). Brussels. Belgian Health Care Knowledge Centre (KCE). 2012. KCE Reports 178C. DOI: 10.57598/R178C
- IQVIA. Burden of Acute Respiratory Infections (BARI) study; 2020 (data on file).
- SNS—Monitorização diária do serviço de urgencia; 2021. Available from: https://www.sns.gov.pt/monitorizacao-do-sns/servicos-de-urgencia/
- Sciensano. Belgian Institute for Health—seasonal influenza surveillance. Available from: https://www.sciensano.be/en/health-topics/influenza/role-0
- StatBel. Causes of death by month, sex, age group and region. Available from: https://statbel.fgov.be/en/open-data/causes-death-month-sex-age-group-and-region
- SNS—Portal da transparencia; 2021. Available from: https://transparencia.sns.gov.pt/explore/?sort=title&q=gripe
- Jacks A, Ollgren J, Ziegler T, et al. Influenza-associated hospitalisations in Finland from 1996 to 2010: unexpected age-specific burden during the influenza A(H1N1)pdm09 pandemic from 2009 to 2010. Euro Surveill. 2012;17(38):20276.
- Finnish Institute for Health and Welfare (THL). Vaccine coverage. Available from: https://www.thl.fi/roko/rokotusrekisteri/atlas/atlas.html?show=influenza
- Portal de dados abertos da Administração Pública. Available from: https://dados.gov.pt/pt/datasets/taxa-de-cobertura-da-vacina-antigripal-sazonal-1/
- Finnish Institute for Health and Welfare (THL). National Infectious Diseases Register [cited 2021 Feb 10].
- Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661–1665.
- Official Statistics of Finland. Medicinal products database [web publication]. Helsinki: Kela; 2021. Available from: https://www.kela.fi/web/en/medicinal-products-database
- Fleming DM, Andrews NJ, Ellis JS, et al. Estimating influenza vaccine effectiveness using routinely collected laboratory data. J Epidemiol Community Health. 2010;64:1062–1067.
- Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121(4):258–264.
- Becker DL, Chit A, DiazGranados CA, et al. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors. Hum Vaccin Immunother. 2016;12(12):3036–3042.
- Chit A, Roiz J, Briquet B, et al. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. Vaccine. 2015;33(5):734–741.
- Colrat F, Thommes E, Largeron N, et al. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: a systematic literature review. Vaccine. 2021;39(Suppl 1):A42–A50.
- van Aalst R, Russo EM, Neupane N, et al. Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US veteran population: estimating the impact on hospitalization cost for cardio-respiratory disease. Vaccine. 2019;37(32):4499–4503.
- World Health Organization. Influenza; 2019 [cited 2020 May 1]. Available from: https://www.who.int/biologicals/vaccines/influenza/en/
- Bonmarin I, Belchior E, Lé vy-Bruhl D. Impact of influenza vaccination on mortality in the French elderly population during the 2000-2009 period. Vaccine 2015;33:1099–1101.